Objectives: The objective of this study was to design and evaluate the potential of a new topical treatment for oral mucositis.

Methods: Poly(DL-lactic-co-glycolic) (PLGA) nanoparticles (NPs) and Poloxamer 407 (PLX)/Hydroxypropyl methyl cellulose (HPMC) hydrogel matrix (HG) were used as combined carriers for benzydamine HCl (BNZ). BNZ loaded PLGA nanoparticles were assessed for their particle size, PDI, zeta potential and entrapment efficiency. Scanning electron microscopy, thermosensitivity study, mucoadhesion study, in vitro release and in vivo investigation were used to characterize the combined BNZ loaded PLGA NPs-HG.

Results: Negatively charged NPs with an average diameter of 139±49.2 nm were incorporated into PLX/HPMC HG bases. The gelation temperature of BNZ-PLGA-NPs-HGs ranged between 31°C and 36.5°C. When diluted with saliva simulated fluid, BNZ-PLGA-NPs-HGs preserved their gelation properties. Mucoadhesion was found lower for formulations prepared with PLX without HPMC. An increase in the concentrations of PLX from 10 to 30% resulted in an increase in adhesion. Both PLGA-NPs and PLGA-NPs-HG provided a biphasic drug release profile while BZN-HG provided monophase zero order release pattern. The in vivo study showed that animal groups treated with BZN-HG and BZN-PLGA-NPs-HG showed a significantly higher reduction percentage in ulcer surface area compared to those treated with BZN-PLGA-NPs. BZN-PLGA-NPs-HG group needed 10 d of treatment to complete healing versus 16 d, 14 d and 12 d for the complete healing of groups with no treatment, treated with BZN-PLGA-NPs and treated with BZN-HG, respectively.

Conclusion: BZN-PLGA-NPs-HG could represent a promising mean for the effective treatment of oral mucositis induced by cancer therapy.

Keywords: Mucositis, PLGA nanoparticles, Thermosensitive hydrogel, Mucoadhesive hydrogel, In vivo

INTRODUCTION

Mucositis is a highly common side effect to cancer treatments [1]. It is characterized by painful lesions and odynophagia. Mucositis often degrades patients’ quality of life and affects compliance with anticancer therapies to the extent of interrupting treatment [2-4]. Oral mucositis is reported in about 100% of patients on high-dose chemotherapy, in 80% of patients with head and neck malignancies and who are treated with radiotherapy and in 40% of patients receiving conventional doses of cytotoxic chemotherapy [5]. To our knowledge, there is no approved method for either the prevention or the treatment of mucositis [2] except for some therapeutic strategies which depend on the use of direct cytoprotectants such as laser, succrelate, corticosteroids, silver nitrate, vitamins and antioxidants, cryotherapy and indirect cytoprotectants including antimicrobial agents and haematopoietic growth factors [2]. BNZ-HCl is a nonsteroidal drug that possesses analgesic, anesthetic, anti-inflammatory, antipruritic and antimicrobial properties [6]. BZN is suggested to exert its action through suppressing selected pro-inflammatory cytokine production which is hypothesized to be one major mechanism of oral mucositis [6]. BZN-HCl is used as a mouthwash or mouth spray in a concentration of 0.15% [7]. However, such forms show a short residence time in the buccal cavity, therefore, it is difficult to expect an effective treatment.

Over the past few decades, there has been considerable interest in the development of biodegradable polymeric drug carriers. PLGA is one of the most attractive biodegradable synthetic polymers approved by the FDA for human use [8-10], for its safety profile [8], biocompatibility, as well as its tunable mechanical properties and ability to effectively deliver the drug to the target site following a controllable degradation into metabolite monomers, glycolic acid and lactic acid [8] which are further metabolized by the body via the Krebs cycle [11, 12]. However, when PLGA NPs are applied directly to the buccal mucosa, they are drained rapidly through the salivary action, which leads to their rapid elimination through involuntary swallowing [13, 14]. For this reason, the development of mucoadhesive preparations for buccal administration of PLGA nanoparticles is important. HG with mucoadhesive and thermosensitive properties represent a promising option, since mucositis allow close contact with the buccal mucosa, providing adhesiveness and prolonging the residence time of the drug [15, 16] and in situ thermosensitivity allows easy application and quick spreading [17] of the formulation onto the site of action at room temperature whereas, the subsequent gelation enhance the hydrogel’s mucoadhesive property. Pluronic®/poloxamers are a group of polymers which exhibits thermo-reversible property in aqueous solutions. Poloxamer 407 is widely used as a gelling agent in the concentration range of 20 to 30%. Poloxamer 407 not only can self-assemble to form micelles but is also known to form gels in situ in response to a temperature increase [18-21]. However, they generally have a high critical gelation concentration (CGCs) and poor resilience [22]. In addition, the hydrogels of poloxamer 407 formed above the sol gel transition temperature generally exhibit no or poor bioadhesive properties [23]. Therefore, formulating poloxamer 407 with other bioadhesive polymers such hydroxy-propyl-methylcellulose (HPMC), will decrease the used concentration, increase its mucoadhesion and in turn enhance its ability to withstand salivation, tongue movements and swallowing for a significant period of time [24].

The aim of the study was to evaluate the impact of BZN-PLGA-NP-HG on the treatment of oral mucositis in vivo.

MATERIALS AND METHODS

Materials

Benzydamine Hydrochloride, a kind gift from EIPICO, Egypt. Hydroxy propyl methyl cellulose, a kind gift from EIPICO, Egypt. Poloxamer 407, Purchased from Sigma, USA. Poly (lactic-co-glycolic)
polymer; 50:50 (PLGA 50:50) was a kind gift from PURAC®. Other materials were of analytical grade.

Preparation of free (PLGA NPs) and BZN HCl loaded PLGA nanoparticles (BZN-PLGA-NPs)

The porous PLGA nanoparticles loaded with BZN HCl were prepared using the water–oil–water emulsion solvent evaporation method. Briefly, 100 mg PLGA were dissolved in 4 ml dichloromethane and placed in an ice bath, then 0.8 ml of distilled water was added to the PLGA solution dropwise. The resulting mixture was emulsified by ultra-sonication in an ice bath for 2 min, after which a solution of ammonium bicarbonate (100 mg/ml, 0.1 ml) was added and the mixture was re-sonicated in an ice bath for 30 s to form the primary emulsion. The primary emulsion was poured into 50 ml of poly-(vinyl alcohol) aqueous solution (0.5% w/v) and homogenized at 3000 rpm in an ice bath for 3 min. The resulting emulsion was added to 50 ml of distilled water, and the dichloromethane was allowed to evaporate under magnetic stirring at room temperature over 5 h. Finally, the formed nanoparticles were collected by centrifugation at 5000 rpm for 15 min, washed with distilled water three times, and then lyophilized. The dried porous nanoparticles were stored at −20 °C until use.

For the preparation of BZN-PLGA-NPs, a specific amount of the drug equivalent to 0.15% w/v final concentration was added to distilled water before addition to the PLGA dichloromethane solution and further steps were continued as mentioned above.

Characterization of PLGA nanoparticles

Particle size, PDI and zeta potential

The particle size, PDI and zeta potential of drug-free PLGA NPs and BZN-PLGA-NPs were determined by dynamic light scattering (DLS) incorporated into the blank HG bases prepared using high speed stirring for 3 min at 1000 rpm, in a concentration of 50% (w/w) of the BNZ-PLGA-NPs dispersion into HG. The final concentration of BNZ in all BZN-PLGA-NPs-HG formulation was set to 0.15% w/v.

<table>
<thead>
<tr>
<th>Formulation</th>
<th>PLX (g)</th>
<th>Drug Concentration (%)</th>
<th>HPMC (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F0</td>
<td>10</td>
<td>0.15</td>
<td>0</td>
</tr>
<tr>
<td>F00</td>
<td>20</td>
<td>0.15</td>
<td>0</td>
</tr>
<tr>
<td>F000</td>
<td>30</td>
<td>0.15</td>
<td>0</td>
</tr>
<tr>
<td>F1</td>
<td>10</td>
<td>0.15</td>
<td>0.25</td>
</tr>
<tr>
<td>F2</td>
<td>10</td>
<td>0.15</td>
<td>0.25</td>
</tr>
<tr>
<td>F3</td>
<td>10</td>
<td>0.15</td>
<td>1</td>
</tr>
</tbody>
</table>

Mucoadhesion evaluation

Mucin-interaction method was used to evaluate the mucoadhesion properties of the prepared hydrogels through determining the changes in zeta potential. Porcine mucin powder was hydrated in demineralized water at 4 °C for 12 h. The mucin solution was then adjusted to pH 7.4 and diluted to a final concentration of 1% (w/v) using 0.1 M phosphate buffer (pH 7.4). The mucin solution was centrifuged at 5000 rpm for 30 min, the resulting supernatant was filtered and used in the mucoclinench experiment. Equal volumes of each prepared hydrogel, one at a time, and the 1% (w/v) mucin particles solution were mixed using a vortex for 1 min. The zeta potential of each of the mucin solution and the mixtures was measured using Zetasizer and the changes in the zeta potential following interaction of the hydrogel with the negatively charged mucin [27] was investigated.

In vitro drug release

The in vitro release characteristics of BZN HCl from HG matrix, PLGA-NPs and PLGA-NPs-HG were studied. Samples of each of the tested formulations containing predetermined drug content of 0.15% w/w were placed first in a dialysis bag then in a dissolution apparatus containing 350 ml phosphate buffer of pH 6.8±0.5 at 37±0.5 °C. The stirring speed was set to 50 rpm. Aliquots of 2 ml were withdrawn at previously specified time intervals and replaced.
by equal volumes of fresh buffer solution. Samples were measured spectrophotometrically at $\lambda_{max}$ 305 nm [28].

**In vivo animal study**

The *in vivo* protocol was carried out in accordance with the Guidelines laid down by the National Institute of Health (NIH) in the USA regarding the care and use of animals for experimental procedures and in accordance with local laws and regulations. Twenty-four male albino rabbits weighing 2.5–3.0 kg provided by the animal house of Assiut University, Egypt. Animal ethical approval was obtained from the Ethics Committee of the Faculty of Pharmacy, Al-Azhar University (approval code pharmaceut05) were used for this study. Animals have been acclimatized for one week. Each group of rabbits was placed in a separate cage with free access to food and drink. The cage environment was controlled to optimum humidity and 25 °C temperature.

Oral mucositis was induced by cancer chemotherapy [29]. Rabbits were administered an intraperitoneal injection of 5-fluorouracil on 5, 3 and 1 d prior to the experiment at a dose of 50 mg/kg body weight. On the day of the experiment, mice were anesthetized, and the model of oral mucositis was enhanced through creating aseptic tissue necrosis in all 24 animals using round filter paper soaked in 15 ml of 50% acetic acid. In order to create round ulcers and facilitate measurements and follow up, the acid-soaked paper was pressed onto the labial gingival tissue of the rabbits for 60 s. Animals were divided into four groups, each of 6 animals; Group 1: Control group where animals received no treatment, Group 2: where animals received BZN-HCl treatment, Group 3: where animals received BZN-PLGA-NPs treatment and Group 4: where animals received BZN-PLGA-NPs-HG treatment. The treatment started 24 h after ulcer initiation (day 1). The dose of BZN HCl used for groups 2 and 3 was 1 mg/kg drug applied twice daily. The area of the ulcer measured on day 1 before treatment application was considered the baseline reading. The progress and healing of the buccal ulcer were evaluated by subtracting the daily reading from the ulcer measurement at day 1.

**Statistical analysis**

The statistical analysis was carried out using Graphpad Software Instat (version 6; GraphPad Software, Inc., La Jolla, CA, USA). The level of significance was set at probability $P<0.05$.

**RESULTS AND DISCUSSION**

**PLGA nanoparticles**

Free and BZN loaded PLGA nanoparticles were prepared and characterized for their physiochemical properties including particle size, PDI and zeta potential. BZN-PLGA-NPs were further characterized for their entrapment efficiency (%) (table 2). Experimental conditions for the preparation of PLGA nanoparticles including the sonication time and amplitude were optimized after preliminary trials (data not shown) to 100% amplitude and 12 min sonication time [30].

The particle size of BZN free PLGA-NPs was found to be 69.27 ± 5.19 nm while that of BZN-PLGA-NPs was found to be a bit higher (90.81 ± 4.92 nm), similar particle size ranges for free and loaded PLGA NPs were previously reported [31, 32]. PDI showed uniform size distribution. Zeta potential of both free and BZN loaded PLGA-NPs were found to be -29.17 and -26.51, respectively indicating the formation of stable particles. Both formulations showed a negative charge with BZN-PLGA-NPs showing slightly lower values than free PLGA NPs. Negative values of zeta potential obtained for PLGA-NPs might be due to the presence of terminal carboxyl groups in the polymer. The percentage of incorporated BZN in the polymeric matrix was found to be 80% which agrees with the findings of Abrego et al., conducted in 2014 [33].

| Table 2: Particle size, PDI, zeta potential and entrapment efficiency of PLGA-NPs |
|---|---|---|
| **Free PLGA** | **BZN-PLGA-NPs** |
| Particle Size (nm) | 69.27 ± 5.19* | 90.81 ± 4.92* |
| PDI | 0.197 | 0.265 |
| Zeta Potential (mv) | -29.17 | -26.51 |
| EE (%) | - | 79.92 ± 3.10* |

*Results are expresses as mean±SD, n=3.

**Fig. 1: SEM micrograph of BZN-PLGA-NPs-HGs**
Preparation and characterization of PLX/HPMC HG

HPMC together with PLX 407 were used in different w/w ratios to prepare a set of three different formulations of buccal in situ gels (table 1). BZN-PLGA-NPs were incorporated into different HG bases and the properties of BZN-PLGA-NPs-HGs were assessed.

Scanning electron microscopy (SEM)

Fig. 1 reveals the distribution of PLGA-NPs within the porous channels of HG matrix. SEM image shows the nanosized dimensions of PLGA-NPs.

Thermosensitivity study

According to the results shown in table 2, the gelation temperature of all BZN-PLGA-NPs-HGs ranged between 31°C and 36.5°C which renders them all suitable for buccal application [34]. However, it was obvious that the general range of gelation temperatures was higher for HGs formed of PLX solely which reflects the effect of mixing HPMC with PLX on reducing the gelation temperature.

To study the effect of HPMC addition on minimizing the concentration of PLX used, different concentrations of HPMC were mixed with the lowest tested concentration of PLX (10 gm). Interestingly, gelation temperature of PLX/HPMC mixtures (F1, F2 and F3) were modulated to lower values compared to PLX solutions alone (F0, F00 and F000) which suggests that HPMC had a synergistic effect on the gelation of PLX. It has been previously reported that the incorporation of HPMC increased the elastic character of poloxamer gels and decreased their temperature of gelation [23]. PLX is a triblock copolymer which when present in aqueous solution and with increasing temperature, the hydrophobic chains of the copolymer undergo de-solvation due to the breaking of hydrogen bonds previously formed between the solvent and these chains. This promotes hydrophobic interactions among the polyoxypropylene domains and leads to gel formation [35] and at the definite point of gelation, micelles come into contact and organize under a micellar cubic phase [36] and no longer move. Micelle entanglements do not allow micelles to separate easily from each other and thus, forms rigid HG [37]. In the presence of HPMC, the HPMC chains might be able to bridge the poloxamer micelles, thus, leading to the formation of a network of interconnected micelles. This bridging might occur as early as micellization starts and even before the organization of the micelles under a cubic phase [23]. HPMC through its highly hydrophobic nature, and its multiple hydroxyl functional groups, enhances the dehydration of PLX and, consequently the hydrophobic interactions between the poly(propylene oxide) blocks.

The BZN-PLGA-NPs-HG formulations were mixed with SSF to simulate expected dilution in the in vivo circumstances. As shown in table 3, when diluted with 1 ml SSF, all BZN-PLGA-NPs-HGs were found to preserve their gelation properties with non-significant differences in gelation temperature reported with any BZN-PLGA-NPs-HG before and after addition of SSF (*p>0.05). All BZN-PLGA-NPs-HGs retained gelation temperatures below 37°C except for formula F0 containing 10% PLX/0% HPMC which showed a gelation temperature of 37.3°C (table 3).

Table 3: Gelation time measurements of different formulations

<table>
<thead>
<tr>
<th>Formulation</th>
<th>PLX (gm)</th>
<th>Drug concentration (%)</th>
<th>HPMC (gm)</th>
<th>Gelation temp before addition of SSF (°C)</th>
<th>Gelation temp after addition of SSF (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F0</td>
<td>10</td>
<td>0.15</td>
<td>0</td>
<td>36.5±0.45</td>
<td>37.3±1.16</td>
</tr>
<tr>
<td>F00</td>
<td>20</td>
<td>0.15</td>
<td>0</td>
<td>35.8±0.84</td>
<td>35.6±0.28</td>
</tr>
<tr>
<td>F000</td>
<td>30</td>
<td>0.15</td>
<td>0</td>
<td>34.5±0.79</td>
<td>34.5±1.29</td>
</tr>
<tr>
<td>F1</td>
<td>10</td>
<td>0.15</td>
<td>0.25</td>
<td>32.5±0.73</td>
<td>33.3±0.65</td>
</tr>
<tr>
<td>F2</td>
<td>10</td>
<td>0.15</td>
<td>0.5</td>
<td>32.5±1.01</td>
<td>33.2±0.82</td>
</tr>
<tr>
<td>F3</td>
<td>10</td>
<td>0.15</td>
<td>1</td>
<td>31±0.91</td>
<td>32±0.63</td>
</tr>
</tbody>
</table>

*Results are expressed as mean±SD, n=3.

Mucoadhesion study

As stated by Chatterjee and his colleagues in 2017, the success of mucoadhesive formulations depends on the ability of the polymer/s to retain at the mucous layer and to sustain the drug release [44]. Mucoadhesive formulations contain at least one hydrophilic polymer, when this polymer comes in contact to saliva, due to the aqueous nature of saliva, it is wetted, and simultaneously adheres to the mucous with some physical interaction [38]. The polymers employed in BNZ-PLGA-NPs-HG formulations have been denoted as mucoadhesive and, therefore, it would be anticipated that the formulation would display good adherence properties [39-40].

The mucin-particle method was used to evaluate the mucoadhesive properties of BNZ-PLGA-NPs-HG formulations through measuring the changes in the zeta potential of mucin following the addition of different BNZ-PLGA-NPs-HGs one at a time at pH 6.8. The in vitro mucoadhesion test confirmed that all formulations possessed mucoadhesive properties where a significant change (*p<0.5) in the zeta potential of mucin with BNZ-PLGA-NPs-HG compared to free mucin was reported for all formulations (table 4).

Mucoadhesion was found lower for formulations prepared with PLX without HPMC i.e., F0, F00 and F000 containing 10 gm PLX/0 gm HPMC showing the lowest mucoadhesive property, however, an increase in the concentrations of PLX from 10 to 30% resulted in an increase in adhesion. On the other hand, the presence of HPMC with its known mucoadhesive characteristics [41] enhanced mucoadhesion with F3; containing the highest concentration of HPMC, showing the highest mucoadhesive property. It’s worth mentioning that the addition of HPMC to PLX enhanced the mucoadhesion property of the HG inspite of the lower concentration of PLX used which highlights the synergistic influence of the concomitant presence of PLX and HPMC in the HG. The mucoadhesive force increased in formulations F1, F2 and F3 with increasing HPMC concentration from 0.25% to 1% [42]. Cellulose derivatives such as HPMC are considered first generation mucoadhesive polymers [43], they acquire their adhesion property through the formation of H bond between the carboxylic acid group of the cellulose polymer and the glycoprotein of mucin. As the concentration of HPMC in the formulation increases, stronger H bonds are formed causing deeper and stronger attachment of the HG with the mucous layer [44]. Mucoadhesion results are likely to ensure a prolonged adhesion of the HGs at the mucosal surface, following their buccal administration.

Table 4: Effect of the interaction of hydrogel and mucin on Zeta potential

<table>
<thead>
<tr>
<th>Material tested</th>
<th>Zeta potential (mV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mucin</td>
<td>-2098</td>
</tr>
<tr>
<td>Mucin+F0</td>
<td>14.84</td>
</tr>
<tr>
<td>Mucin+F00</td>
<td>12.19</td>
</tr>
<tr>
<td>Mucin+F000</td>
<td>11.51</td>
</tr>
<tr>
<td>Mucin+F1</td>
<td>10.01</td>
</tr>
<tr>
<td>Mucin+F2</td>
<td>7.43</td>
</tr>
<tr>
<td>Mucin+F3</td>
<td>5.29</td>
</tr>
</tbody>
</table>
In vitro drug release

The release of drug from three different formulations was performed: HG, PLGA-NPs and PLGA-NPs-HG. Based on the thermosensitivity and mucoadhesion results, the HG composed of 10 g PLX and 1 g HPMC was selected as the base of HG and PLGA-NPs-HG formulations used in the in vitro release experiment.

As shown in fig. 2, both PLGA-NPs and PLGA-NPs-HG formulations offered a slower release of BZN when compared to HG. PLGA-NPs-HG provided the slowest release of BZN amongst the three tested formulations. The fact that PLGA-NPs were retained within the PLX/HPMC HG matrix might have influenced the release profile of BZN and reduced the initial burst release of the drug molecules [45]. Both PLGA-NPs and PLGA-NPs-HG provided a similar biphasic drug release profile [46]. Compared to BZN-PLGA-NPs, BZN-PLGA-NPs-HG showed a reduced burst release (30.81 at 1.5 h vs 19.6% at 1h, respectively). BZN release from BZN-PLGA-NPs occurred according to two phases. In phase I, the dissolution medium stimulated the through desorption of particles, in addition, it caused the random erosion/diffusion mechanism took place where the erosion of a thicker polymer layer occurred to allow the diffusion of the drug particles in a slower release rate. For PLGA-NPs-HG, the three-dimensional network structure of hydrogels is expected to further delay the release of the drug [47] as the release into the medium is expected to occur in two steps, first the release of the drug from the PLGA-NPs as per the steps mentioned above then the drug followed by drug diffusion through the microchannels of the hydrogel to the external media.

From the analysis of the release profiles (fig. 2), BZN-HG showed faster drug release in comparison to BZN-PLGA-NPs-HGs, in addition, a monophasic zero order release pattern (R^2 = 0.9874) was reported. In the study conducted by Kassab et al., in 2017, a biphasic release profile was reported for gatifloxacin from periodontal bioadhesive gel. The authors attributed the initial burst effect to the drug which is present freely in the gel matrix [48].

After four hours the HG with free BZN exhibited a drug release of 71.26%, while for BZN-PLGA-NPs-HG, the maximum amount released was 45.99%. These results evidenced the ability of PLGA-NPs-HG to offer a sustained drug release of BZN thus, maintaining its presence for a longer time over the affected buccal area. In the study conducted by Ashmoony et al., incorporation of clomipramine in niosomal gel lead to a delayed drug release profile which the authors attributed to the presence of additional diffusion barrier [49].

Fig. 2: Drug release profile of BZN from HG, PLGA-NPs and PLGA-NPs-HG (Results are expressed as mean±SE, n=3)

In vivo study

In order to determine the efficacy of tested formulations on the clinical healing of oral mucositis, the ulcer area was measured on consequent observation days and percentage reduction was recorded. The mucositis model used was adapted from Takeuchi et al., 2018 and Karvanavel et al., 2011 [50-51].

In the present study, the most prominent differences between the groups were observed on day 2. The untreated group showed a worsened ulcer condition. Animal groups 2 and 4 treated with BZN-HG and BZN-PLGA-NPs-HG, respectively showed a significantly higher reduction percentage in ulcer surface area compared to group 3 treated with BZN-PLGA-NPs (p<0.05), which suggests that both treatments may promote early stage healing [50].

The BZN-PLGA-NPs-HG group 4 needed 10 d of treatment to complete healing versus 16 d, 14 d and 12 d for the complete healing of groups 1 (no treatment), 3 (treated with BZN-PLGA-NPs) and 2 (BZN-HG).

From these results (table 5), the high retention in the oral cavity of BZN-PLGA-NPs-HG could be considered the main factor contributing to its enhanced therapeutic outcome. BZN-PLGA-NPs with non-retentive properties showed the lowest reduction percentage on day 2 and the longest treatment period compared to the other two formulations. BZN-HG did not contribute to shortening the treatment period of oral mucositis however, they helped reduce the ulcer area.

Table 5: Average reduction in ulcer surface area for rabbits in different test groups

<table>
<thead>
<tr>
<th>Observation day</th>
<th>Reduction in ulcer area (%)</th>
<th>Group 1’ no treatment</th>
<th>Group 2’ BZN-HG</th>
<th>Group 3’ BZN-PLGA-NPs</th>
<th>Group 4’ BZN-PLGA-NPs-HG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 2</td>
<td>-34.1±2.29</td>
<td>39.82±2.39</td>
<td>17.29±1.29</td>
<td>41.83±3.23</td>
<td></td>
</tr>
<tr>
<td>Day 4</td>
<td>-5.67±0.21</td>
<td>45.19±3.20</td>
<td>39.85±2.19</td>
<td>60.49±1.83</td>
<td></td>
</tr>
<tr>
<td>Day 6</td>
<td>7.20±0.88</td>
<td>61.10±1.93</td>
<td>48.39±2.71</td>
<td>75.50±2.01</td>
<td></td>
</tr>
<tr>
<td>Day 8</td>
<td>29.10±2.10</td>
<td>74.84±5.83</td>
<td>65.30±4.38</td>
<td>93.02±4.32</td>
<td></td>
</tr>
<tr>
<td>Day 10</td>
<td>48.33±3.29</td>
<td>89.28±3.29</td>
<td>83.24±3.28</td>
<td>95.29±6.49</td>
<td></td>
</tr>
<tr>
<td>Day 12</td>
<td>70.17±2.93</td>
<td>92.10±4.85</td>
<td>91.20±4.45</td>
<td>100±5.40</td>
<td></td>
</tr>
</tbody>
</table>

*p<0.05, †Results are expressed as mean±SD, n=6.
CONCLUSION

In the present study, PLGA nanoparticles were prepared, drug loaded and incorporated into six different PLX/HPMC HGs. F3 BZN-PLGA-NPs-HGs showed promising thermosensitive, mucoadhesive and in vitro release properties and when tested on experimental animal’s model, it was able to successfully contribute to the effective treatment of mucositis in a reduced time interval.

AUTHORS CONTRIBUTIONS

All the authors have contributed equally

CONFLICTS OF INTERESTS

Declared none

REFERENCES


